Oncternal Therapeutics Inc logo

ONCT - Oncternal Therapeutics Inc Share Price

$2.99 0.1  3.1%

Last Trade - 05/06/20

Micro Cap
Market Cap £39.9m
Enterprise Value £27.2m
Revenue £2.01m
Position in Universe 4600th / 6321
Unlock ONCT Revenue
Relative Strength (%)
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Financial Summary
FINANCIAL BRIEF: : For the three months ended 31 March 2020, Oncternal Therapeutics Inc revenues increased 23% to $578K. Net loss increased from $2.3M to $4.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects other increase from $918K to $2.4M (expense), Other Research and development expenses increase of 37% to $2.6M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


ONCT Revenue Unlock ONCT Revenue

Net Income

ONCT Net Income Unlock ONCT Revenue

Normalised EPS

ONCT Normalised EPS Unlock ONCT Revenue

PE Ratio Range

ONCT PE Ratio Range Unlock ONCT Revenue

Dividend Yield Range

ONCT Dividend Yield Range Unlock ONCT Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ONCT EPS Forecasts Unlock ONCT Revenue
Profile Summary

Oncternal Therapeutics, Inc., formerly GTX, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of product candidates for the treatment of cancers. Its pipeline includes cirmtuzumab, TK-216 and chimeric antigen receptor T-cell (CAR-T). Its cirmtuzumab product candidate is an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) monoclonal antibody. Cirmtuzumab is in a Phase-I/II clinical trial in combination with ibrutinib for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). TK216 is a small-molecule compound designed to inhibit the biological activity of E26 transformation-specific (ETS) oncoproteins. TK216 is being evaluated in combination with vincristine in a Phase-I clinical trial in patients with relapsed or refractory Ewing sarcoma. Its CAR-T product candidate targets ROR-1 and is in preclinical development as a treatment for hematologic cancers and solid tumors.

Last Annual December 31st, 2019
Last Interim March 31st, 2020
Incorporated September 4, 2003
Public Since February 3, 2004
No. of Shareholders: 156
No. of Employees: 11
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Capital Market
Shares in Issue 17,336,013
Free Float (0.0%)
Eligible for
ONCT Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ONCT
Upcoming Events for ONCT
Thursday 11th June, 2020
Oncternal Therapeutics Inc Annual Shareholders Meeting
Monday 8th June, 2020
Oncternal Therapeutics Inc at Biotechnology Industry Organization (BIO) International Convention (Virtual)
Frequently Asked Questions for Oncternal Therapeutics Inc
What is the Oncternal Therapeutics Inc share price?

As of 05/06/20, shares in Oncternal Therapeutics Inc are trading at $2.99, giving the company a market capitalisation of £39.9m. This share price information is delayed by 15 minutes.

How has the Oncternal Therapeutics Inc share price performed this year?

Shares in Oncternal Therapeutics Inc are currently trading at $2.99 and the price has moved by -68.61% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Oncternal Therapeutics Inc price has moved by -71.42% over the past year.

What are the analyst and broker recommendations for Oncternal Therapeutics Inc?

Of the analysts with advisory recommendations for Oncternal Therapeutics Inc, there are there are currently 0 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Oncternal Therapeutics Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Oncternal Therapeutics Inc next release its financial results?

Oncternal Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the Oncternal Therapeutics Inc dividend yield?

Oncternal Therapeutics Inc does not currently pay a dividend.

Does Oncternal Therapeutics Inc pay a dividend?

Oncternal Therapeutics Inc does not currently pay a dividend.

When does Oncternal Therapeutics Inc next pay dividends?

Oncternal Therapeutics Inc does not currently pay a dividend.

How do I buy Oncternal Therapeutics Inc shares?

To buy shares in Oncternal Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Oncternal Therapeutics Inc?

Shares in Oncternal Therapeutics Inc are currently trading at $2.99, giving the company a market capitalisation of £39.9m.

Where are Oncternal Therapeutics Inc shares listed? Where are Oncternal Therapeutics Inc shares listed?

Here are the trading details for Oncternal Therapeutics Inc:

Country of listing: United States
Exchange: NAQ
Ticker Symbol: ONCT
What kind of share is Oncternal Therapeutics Inc?

Based on an overall assessment of its quality, value and momentum, Oncternal Therapeutics Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Oncternal Therapeutics Inc share price forecast 2020?

Shares in Oncternal Therapeutics Inc are currently priced at $2.99. At that level they are trading at 48.28% premium to the analyst consensus target price of 0.00.

Analysts covering Oncternal Therapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of -1.11 for the next financial year.

How can I tell whether the Oncternal Therapeutics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Oncternal Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been -46.07%. At the current price of $2.99, shares in Oncternal Therapeutics Inc are trading at -31.15% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Oncternal Therapeutics Inc PE Ratio?

We were not able to find PE ratio data for Oncternal Therapeutics Inc.

Who are the key directors of Oncternal Therapeutics Inc?

Oncternal Therapeutics Inc's management team is headed by:

Hazel Aker - GCN
James Breitmeyer - PRE
Richard Vincent - CFO
Robert Wills - DRC
Michael Carter - IND
Frank Hsu - OTH
Gunnar Kaufmann - CSO
Igor Bilinsky - OTH
Man Cho - DRC
Who are the major shareholders of Oncternal Therapeutics Inc?

Here are the top five shareholders of Oncternal Therapeutics Inc based on the size of their shareholding:

Shanghai Pharmaceutical USA Inc Corporation
Percentage owned: 14.39% (2.50m shares)
Armistice Capital LLC Hedge Fund
Percentage owned: 9.09% (1.58m shares)
Hyde (Joseph R III) Individual Investor
Percentage owned: 5.67% (983k shares)
Pyramid Peak Foundation Corporation
Percentage owned: 3.62% (627k shares)
Creative Planning, Inc. Investment Advisor/Hedge Fund
Percentage owned: 2.81% (488k shares)
Similar to ONCT
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.